Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
SELECTIVE BCRP/ABCG2 TRANSPORTER INHIBITORS AS AGENTS TO ABOLISH RESISTANCE TO ANTI-CANCER AGENTS
Document Type and Number:
WIPO Patent Application WO/2021/014229
Kind Code:
A1
Abstract:
The present invention relates to a compound of formula (I) or an enantiomer, to a pharmaceutically acceptable salt or solvate of this compound, or to a mixture thereof, wherein the core A, the substituents Z, Y and R1i are as defined in the present application.

More Like This:
Inventors:
BOUMENDJEL AHCÈNE (FR)
FALSON PIERRE (FR)
MORENO ALEXIS (FR)
PERES BASILE (FR)
ROUSSEL EMILE (FR)
Application Number:
IB2020/055168
Publication Date:
January 28, 2021
Filing Date:
June 01, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV GRENOBLE ALPES (FR)
CENTRE NAT RECH SCIENT (FR)
UNIV CLAUDE BERNARD LYON (FR)
International Classes:
C07D311/66; A61K31/352; A61P35/00; C07D405/12; C07D405/14; C07K5/06; C07K5/062
Foreign References:
Other References:
AMANDA DO ROCIO ANDRADE PIRES ET AL: "New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 122, 2016, pages 291 - 301, XP029705909, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2016.05.053
EVELYN WINTER ET AL: "Structure-Activity Relationships of Chromone Derivatives toward the Mechanism of Interaction with and Inhibition of Breast Cancer Resistance Protein ABCG2", JOURNAL OF MEDICINAL CHEMISTRY,, vol. 56, no. 24, 2013, pages 9849 - 9860, XP002784593, DOI: 10.1021/JM401649J
GLAUCIO VALDAMERI ET AL: "Substituted Chromones as Highly Potent Nontoxic Inhibitors, Specific for the Breast Cancer Resistance Protein", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 2, 2012, pages 966 - 970, XP055649683, ISSN: 0022-2623, DOI: 10.1021/jm201404w
BORST, P.ELFERINK, R. O.: "Mammalian ABC Transporters in Health and Disease", ANNU. REV. BIOCHEM., vol. 71, no. 1, 2002, pages 537 - 592, XP002959942, DOI: 10.1146/annurev.biochem.71.102301.093055
LINTON, K. J.: "Structure and Function of ABC Transporters", PHYSIOLOGY, vol. 22, no. 2, 2007, pages 122 - 130
SHAROM, F. J.: "ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance", PHARMACOGENOMICS, vol. 9, no. 1, 2008, pages 105 - 127, XP055038488, DOI: 10.2217/14622416.9.1.105
LESLIE, E. M.DEELEY, R. G.COLE, S. P. C.: "Multidrug Résistance Proteins: Role of P-Glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in Tissue Defense", TOXICOL. APPL. PHARMACOL., vol. 204, no. 3, 2005, pages 216 - 237, XP004858694, DOI: 10.1016/j.taap.2004.10.012
ECKFORD, P. D. W.SHAROM, F. J.: "ABC Efflux Pump-Based Résistance to Che-motherapy Drugs", CHEM. REV., vol. 109, no. 7, 2009, pages 2989 - 3011
BUGDE, P.BISWAS, R.MERIEN, F.LU, J.LIU, D.-X.CHEN, M.ZHOU, S.LI, Y.: "The Therapeutic Potential of Targeting ABC Transporters to Combat Multi-Drug Résistance", EXPERT OPIN. THER. TARGETS, vol. 21, no. 5, 2017, pages 511 - 530
LI, Y.HAYMAN, E.PLESESCU, M.PRAKASH, S. R.: "Synthesis of Potent BCRP Inhibitor-Kol43", TETRAHEDRON LETT., vol. 49, no. 9, 2008, pages 1480 - 1483, XP022439753, DOI: 10.1016/j.tetlet.2007.12.130
LIU, K.ZHU, J.HUANG, Y.LI, C.LU, J.SACHAR, M.LI, S.MA, X.: "Metabolism of KO 143, an ABCG2 Inhibitor", DRUG METAB. PHARMACOKINET., vol. 32, no. 4, 2017, pages 193 - 200
WEIDNER, L. D.ZOGHBI, S. S.LU, S.SHUKLA, S.AMBUDKAR, S. V.PIKE, V. W.MULDER, J.GOTTESMAN, M. M.INNIS, R. B.HALL, M. D.: "The Inhibitor Ko143 Is Not Spécifié for ABCG2", J. PHARMACOL. EXP. THER., vol. 354, no. 3, 2015, pages 384 - 393
ALLEN, J. D.VAN LOEVEZIJN, A.LAKHAI, J. M.VAN DER VALK, M.VAN TELLINGEN, O.REID, G.SCHELLENS, J. H. M.KOOMEN, G.-J.SCHINKEL, A. H.: "Potent and Specific Inhibition of the Breast Cancer Résistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C", MOL. CANCER THER., vol. 1, no. 6, 2002, pages 417, XP002247386
HONORAT, M.GUITTON, J.GAUTHIER, C.BOUARD, C.LECERF-SCHMIDT, F.PERES, B.TERREUX, R.GERVOT, H.RIOUFOL, C.BOUMENDJEL, A. ET AL.: "MBL-II-141, a Chromone Derivative, Enhances Irinotecan (CPT-11) Anticancer Efficiency in ABCG2-Positive Xenografts", ONCOTARGET, vol. 5, no. 23, 2014, pages 11957 - 11970
HÉNIN, E.HONORÂT, M.GUITTON, J.DI PIETRO, A.PAYEN, L.TOD, M.: "Pharmacokinetic Interactions in Mice between Irinotecan and MBL-11-141, an ABCG2 Inhibitor: Irinotecan MBLI-11-141 Interaction", BIOPHARM. DRUG DISPOS., 2017
VALDAMERI, G.GENOUX-BASTIDE, E.PERES, B.GAUTHIER, C.GUITTON, J.TERREUX, R.WINNISCHOFER, S. M. B.ROCHA, M. E. M.BOUMENDJEL, A.DI PI: "Substituted Chromones as Highly Potent Nontoxic Inhibitors, Specific for the Breast Cancer Résistance Protein", J. MED. CHEM., vol. 55, no. 2, 2012, pages 966 - 970, XP055649683, DOI: 10.1021/jm201404w
LECERF-SCHMIDT, F.PERES, B.VALDAMERI, G.GAUTHIER, C.WINTER, E.PAYEN, L.DI PIETRO, A.BOUMENDJEL, A.: "ABCG2: Recent Discovery of Potent and Highly Selective Inhibitors", FUTURE MED. CHEM., vol. 5, no. 9, 2013, pages 1037 - 1045
WINTER, E.LECERF-SCHMIDT, F.GOZZI, G.PERES, B.LIGHTBODY, M.GAUTHIER, C.OZVEGY-LACZKA, C.SZAKACS, G.SARKADI, B.CRECZYNSKI-PASA, T. : "Structure-Activity Relationships of Chromone Derivatives toward the Mechanism of Interaction with and Inhibition of Breast Cancer Résistance Protein ABCG2", J. MED. CHEM., vol. 56, no. 24, 2013, pages 9849 - 9860, XP002784593, DOI: 10.1021/jm401649j
PIRES, A. DO R. A.LECERF-SCHMIDT, F.GURAGOSSIAN, N.PAZINATO, J.GOZZI, G. J.WINTER, E.VALDAMERI, G.VEALE, A.BOUMENDJEL, A.DI PIETRO: "New, Highly Potent and Non- Toxic, Chromone Inhibitors of the Human Breast Cancer Résistance Protein ABCG2", EUR. J. MED. CHEM., vol. 122, 2016, pages 291 - 301, XP029705909, DOI: 10.1016/j.ejmech.2016.05.053
Attorney, Agent or Firm:
CABINET CHAILLOT (FR)
Download PDF: